Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease

  • STATUS
    Recruiting
  • End date
    Mar 31, 2022
  • participants needed
    10
  • sponsor
    Kyoto University
Updated on 26 January 2021
Investigator
Haruhiko Banno, MD, PhD
Primary Contact
Osaka University (4.1 mi away) Contact
+6 other location
dementia
psychiatric disorder
mini-mental state examination

Summary

To investigate the safety and efficacy of an orally administered dose of TW-012R in patients with Alzheimer's disease bearing PSEN1 (presenilin 1) mutations (PSEN1-AD), using a placebo group as a control. In addition, long-term safety will be examined in an open-label extension trial.

Details
Condition Familial Alzheimer Disease (FAD), PSEN1 Mutation, Familial Alzheimer Disease (FAD), Familial Alzheimer Disease (FAD), Familial Alzheimer Disease (FAD), Familial Alzheimer Disease (FAD), Familial Alzheimer Disease (FAD), Familial Alzheimer Disease (FAD), Familial Alzheimer Disease (FAD), Familial Alzheimer Disease (FAD), Familial Alzheimer Disease (FAD), Familial Alzheimer Disease (FAD)
Treatment placebos, bromocriptine
Clinical Study IdentifierNCT04413344
SponsorKyoto University
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Alzheimer's disease patients with PSEN1 mutations
Patients diagnosed with "probable AD" according to the diagnostic guideline of NIA-AA or "probable Alzheimer-type dementia" according to the diagnostic criteria for Alzheimer's disease specified in DSM-5
An MMSE-J score of <= 25
Patients whose cognitive function and everyday function are obviously impaired based on their medical record or information provided by a person who knows the patient well
Patients for whom intellectual disability and mental disorders other than dementia can be ruled out based on their academic background, work history, and life history
Patients with a reliable and close relationship with a partner/caregiver
Age>=20 years at the time of giving informed consent
Written informed consent has been obtained from the patient or his/her legally acceptable representative to participate in this trial

Exclusion Criteria

Difficulty with the oral intake of tablets
Patients receiving anti-dementia drugs who have changed the dosing regimen during the 2 months prior to giving informed consent
Patients with dementia due to pathology other than Alzheimer's disease (e.g., vascular dementia, frontotemporal dementia, Lewy body dementia, progressive supranuclear palsy, corticobasal degeneration, Huntington's disease, and prion disease)
Presence of clinically relevant or unstable mental disorders. Patients with major depression in remission can be enrolled
Imminent risk of self-harm or harm to others
Body mass index (BMI) of <= 17 or >= 35
Patients with a history of alcohol dependence, drug dependence, or drug abuse within the 5 years before providing informed consent
HBs antigen positive
Anti-HIV antibody positive
Anti-HTLV-1 antibody positive
Patients with an active infection, such as hepatitis C and syphilis (STS/TPHA)
Patients with the following liver function values on the test before enrollment
AST(GOT) > 4.0 x Upper limit of the institutional reference range or
ALT (GPT) > 4.0 x Upper limit of the institutional reference range
Patients who have uncontrolled, clinically significant medical conditions (e.g., diabetes melitus, hypertension, thyroid/endocrine disease, congestive cardiac failure, angina pectoris, cardiac/gastrointestinal disease, dialysis, and abnormal renal function with an estimated CLcr < 30 mL/min)within 3 months prior to giving informed consent in addition to the underlying disease to be investigated in the trial and for whom the investigator or sub-investigator considers that there is a significant medical risk in the patient's participation in the trial
Patients with long QT syndrome or tendency toward prolonged QTc interval (male: >=470 msec, female: >= 480 msec), or patients with a history/complication of torsades de pointes
Patients with a history of malignancies within 5 years prior to providing informed consent. However, patients with the following diseases can be enrolled if they are treated appropriately
Skin cancer (basal cell, squamous cell)
Cervical carcinoma in situ
Localized prostate cancer
Malignancies that have not recurred for at least 3 years since surgery and the patient's physician has determined that the risk of recurrence is low
Patients with clinically significant vitamin B1/B12 deficiency or folic acid deficiency within 6 months prior to giving informed consent
Patients who have participated in other clinical research/trials involving interventions within the 3 months prior to providing informed consent
Patients who have previously received bromocriptine or TW-012R
Patients with a history of hypersensitivity to bromocriptine or ergot alkaloids
Patients with current or a history of thickened heart valve cusps, restricted heart valve motion, and the associated heart valve lesions, such as stenosis, confirmed by echocardiography
Pregnant females, lactating females, females who may be pregnant, and females who wish to become pregnant
Other patients who are considered inappropriate to participate in this trial at the discretion of the investigator or sub-investigator
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note